Biosimilar Peptide Regulatory Framework — BPCI Act, Analytical Similarity, and Global Harmonization

Executive Summary

The emergence of biosimilar peptides and follow-on biologics represents one of the most significant developments in the regulatory landscape for therapeutic peptides, driven by the expiration of patents and exclusivity periods for pioneering biologic products and the public health imperative to expand patient access and reduce healthcare costs. This article provides a comprehensive examination of the biosimilar regulatory framework established by the Biologics Price Competition and Innovation (BPCI) Act of 2009, including the 351(k) abbreviated licensure pathway, the stepwise analytical similarity assessment paradigm, comparability protocol design, interchangeability standards, and global regulatory harmonization efforts led by the World Health Organization (WHO), the International Council for Harmonisation (ICH), and bilateral regulatory collaborations. The discussion encompasses the unique scientific challenges of demonstrating biosimilarity for peptide therapeutics — including the analytical characterization of complex peptide structures, the assessment of clinically meaningful differences, and the evolving regulatory expectations for interchangeability designation — and provides a forward-looking perspective on the convergence of global biosimilar standards.

Background

The concept of biosimilarity emerged from the recognition that biologic products — including recombinant therapeutic proteins and certain peptides — are fundamentally different from small-molecule drugs in ways that make the traditional generic drug paradigm inappropriate. Unlike small molecules, which can be fully characterized by analytical chemistry and reproduced with identical structure, biologics are complex macromolecules whose structure and function depend not only on amino acid sequence (primary structure) but also on higher-order structure (folding, aggregation state), post-translational modifications (glycosylation, phosphorylation, disulfide bond formation), and the manufacturing process itself — a principle famously captured in the phrase "the process is the product." Consequently, a biologic product manufactured by a different company using a different cell line, different culture conditions, and different purification processes is not an identical copy of the reference product; it is a similar — "biosimilar" — product that must be demonstrated to have no clinically meaningful differences from the reference product in terms of safety, purity, and potency.

The regulatory framework for biosimilars was established in the United States by the BPCI Act, enacted as Title VII, Subtitle A of the Patient Protection and Affordable Care Act (ACA) on March 23, 2010. The BPCI Act amended the Public Health Service (PHS) Act to create an abbreviated licensure pathway (Section 351(k)) for biological products demonstrated to be "biosimilar" to or "interchangeable" with an FDA-licensed reference product. This pathway was designed to balance two competing policy objectives: (1) to promote competition and reduce healthcare costs by enabling the entry of biosimilar products following the expiration of reference product exclusivity, and (2) to protect patient safety by requiring a robust demonstration of biosimilarity that accounts for the inherent complexity and heterogeneity of biologic products.

Prior to the BPCI Act, the European Union had already established a biosimilar pathway through Directive 2001/83/EC as amended by Directive 2004/27/EC and Regulation (EC) No 726/2004. The EMA approved the first biosimilar product (Omnitrope, a somatropin — recombinant human growth hormone) in 2006, establishing the analytical, nonclinical, and clinical evidence standards that would inform subsequent global biosimilar frameworks. Japan's PMDA, the WHO, and regulatory authorities in Canada, Australia, South Korea, and many other countries subsequently developed biosimilar guidelines, largely harmonized through the ICH process and bilateral regulatory collaborations.

For peptide therapeutics, the biosimilar framework presents unique challenges and opportunities. Peptides occupy an intermediate space between small-molecule drugs and large biologic products: they are large enough to present some of the characterization challenges associated with biologics (higher-order structure, aggregation, immunogenicity), but typically small enough (especially chemically synthesized peptides of fewer than 40 amino acids) to be characterized with greater precision than monoclonal antibodies or fusion proteins. This intermediate position has led to evolving regulatory expectations for the extent of analytical, nonclinical, and clinical data required to demonstrate biosimilarity for peptide products.

The BPCI Act and the 351(k) Abbreviated Licensure Pathway

Statutory Framework

The BPCI Act created Section 351(k) of the PHS Act, which provides that a biological product may be licensed based on an application demonstrating that it is:

1. Biosimilar to a reference product — meaning that the biological product is "highly similar to the reference product notwithstanding minor differences in clinically inactive components" and that "there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product"
2. Interchangeable with the reference product — meaning that the biological product is biosimilar to the reference product, that it "can be expected to produce the same clinical result as the reference product in any given patient," and that "for a biological product that is administered more than once to an individual, the risk in terms of safety or diminished efficacy of alternating or switching between use of the biological product and the reference product is not greater than the risk of using the reference product without such alternation or switch"

The 351(k) application must include:

• Analytical studies demonstrating that the biological product is "highly similar" to the reference product
• An assessment of animal toxicity (including immunogenicity assessment), unless the FDA determines such studies to be unnecessary
• A clinical study or studies (including immunogenicity and pharmacokinetics/pharmacodynamics) sufficient to demonstrate safety, purity, and potency in one or more appropriate indications for which the reference product is licensed

Critically, the BPCI Act gives the FDA discretion to determine that certain studies are unnecessary for a particular application — a principle described by the FDA as the "totality-of-the-evidence" approach, in which the demonstrating of biosimilarity is based on the entire body of analytical, nonclinical, and clinical data, rather than any single element.

The Totality-of-the-Evidence Approach

The FDA's totality-of-the-evidence approach, articulated in its 2015 guidance "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product," establishes a stepwise, hierarchical framework for demonstrating biosimilarity:

Step 1 — Extensive analytical characterization: The foundation of the biosimilarity demonstration is a comprehensive analytical comparison of the proposed biosimilar product and the reference product. This comparison spans structural characterization (primary structure, higher-order structure, post-translational modifications), physicochemical properties (molecular weight, charge variants, hydrophobicity), functional characterization (biological activity, binding affinity), and purity/impurity profiles (product-related substances, process-related impurities). For peptide products, analytical techniques include HPLC (RP-HPLC, SEC-HPLC, IEX-HPLC), mass spectrometry (intact mass, peptide mapping, MS/MS), spectroscopic methods (CD, FTIR, NMR if appropriate), thermal stability (DSC), and aggregation assessment (DLS, AUC, SEC-MALS).

Step 2 — Nonclinical studies: Based on the outcome of the analytical similarity assessment, the need for nonclinical data is determined on a case-by-case basis. The sponsor may be required to conduct at least one in vivo pharmacodynamic study (if a relevant pharmacodynamic marker is available and sensitive to differences) and at least one animal toxicity study, unless justified by the analytical data. The FDA has indicated that, where analytical similarity is extensive and robust, animal studies may be reduced or waived.

Step 3 — Clinical pharmacology: The clinical development program for a proposed biosimilar typically begins with comparative pharmacokinetic (PK) and, where feasible, pharmacodynamic (PD) studies in healthy volunteers or patients to demonstrate similar exposure and response. PK/PD similarity — typically evaluated by the 90% confidence interval for the geometric mean ratio of Cmax and AUC falling within the predefined acceptance range (usually 80–125%) — is a critical element of the biosimilarity demonstration.

Step 4 — Comparative clinical studies: At least one comparative clinical study in a sensitive indication is typically required, designed to demonstrate no clinically meaningful differences in safety, efficacy, and immunogenicity between the proposed biosimilar and the reference product. The study may be an equivalence design (demonstrating that the treatment difference falls within a predefined equivalence margin) or a non-inferiority design with appropriate margins. The choice of clinical endpoint, patient population, and study duration must be justified.

Step 5 — Integration: The totality of the analytical, nonclinical, and clinical evidence is integrated to reach a conclusion on biosimilarity. Residual uncertainty at any step may be addressed by additional data at subsequent steps, but the overall evidence must provide a convincing demonstration that there are no clinically meaningful differences.

Analytical Similarity Assessment for Peptide Products

The Structural and Functional Characterization Hierarchy

For peptide biosimilars, the analytical similarity assessment is the cornerstone of the biosimilarity demonstration, reflecting the principle that peptides can be characterized more extensively than large biologics. The FDA and EMA have articulated a hierarchical approach to analytical characterization, organized by the nature of the attribute being assessed:

Tier 1 — Most critical quality attributes: Attributes with direct relevance to clinical outcome, typically including biological activity (potency), certain purity attributes, and attributes known to affect immunogenicity or pharmacokinetics. Tier 1 attributes are assessed using statistical equivalence testing, with predefined equivalence margins justified by clinical relevance.

Tier 2 — Quality attributes supporting similarity: Attributes important for product quality but less directly linked to clinical outcome, such as certain physicochemical properties and lower-risk purity attributes. Tier 2 attributes are assessed using quality ranges, typically the mean ± 3 standard deviations of the reference product's measured range, or a predefined acceptance range.

Tier 3 — Attributes for descriptive characterization: Attributes monitored for information and trend analysis, such as certain minor product-related variants. Tier 3 attributes are assessed by graphical comparison and descriptive statistics without formal acceptance criteria.

Key Analytical Methods for Peptide Biosimilarity

Primary structure: Intact mass measurement by high-resolution mass spectrometry, amino acid sequence confirmation by peptide mapping with MS/MS, amino acid analysis for composition assessment, and N-terminal and C-terminal sequencing (Edman degradation and carboxypeptidase digestion, respectively).

Higher-order structure: Far-UV circular dichroism (CD) for secondary structure content comparison, near-UV CD for tertiary structure, intrinsic fluorescence spectroscopy (and, where possible, extrinsic fluorescence with ANS or bis-ANS probes), Fourier-transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC) for thermal stability, and — for peptides where structural differences between products are suspected — nuclear magnetic resonance (NMR) spectroscopy may provide residue-level structural resolution.

Post-translational modifications and product-related variants: Disulfide bond mapping (demonstrating the correct pairing pattern in multi-disulfide peptides), assessment of deamidation (asparagine, glutamine), oxidation (methionine, tryptophan, cysteine), N-terminal pyroglutamate formation, C-terminal truncation, and aggregation (SEC-HPLC, DLS, AUC).

Functional characterization: Potency assays that reflect the mechanism of action — typically receptor binding assays (competitive binding, surface plasmon resonance for kinetics), cell-based functional assays (cAMP accumulation, calcium mobilization, reporter gene assays), and, where applicable, in vivo pharmacodynamic models. The potency assay for a peptide biosimilar should be quantitative and sensitive to changes in product quality that could affect biological activity.

Purity and impurity profile: Product-related impurities (deletion sequences, oxidation products, aggregates, deamidation products) compared quantitatively between the proposed biosimilar and reference product, and process-related impurities (host cell proteins for recombinant peptides, residual solvents, elemental impurities) assessed for comparable levels or — if different — justified as not clinically meaningful.

Comparability Protocols and Manufacturing Changes

The Comparability Paradigm

The concept of comparability — demonstrating that a manufacturing process change does not adversely affect the safety or efficacy of a product — is central to both biosimilar development and product lifecycle management. The comparability paradigm, established in ICH Q5E (Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process), provides a framework for assessing the impact of manufacturing changes.

For biosimilar development, comparability is exercised at two distinct stages:

During product development: As the manufacturing process for the proposed biosimilar is optimized and scaled up, comparability assessments between pre-change and post-change material ensure that process improvements have not inadvertently altered critical quality attributes. These assessments typically rely on extensive analytical characterization supplemented by limited nonclinical or clinical PK/PD bridging data when warranted.

Biosimilar-to-reference product comparability: The final demonstration that the manufacturing process consistently produces a product that is biosimilar to the reference product — the core of the 351(k) submission — requires a comprehensive comparability assessment using the totality-of-the-evidence approach described above.

Post-Approval Changes and Comparability Protocols

Following licensure, biosimilar peptide manufacturers will inevitably need to implement manufacturing changes — improvements in cell culture productivity (for recombinant peptides), changes in synthetic protocols (for chemically synthesized peptides), scale-up to larger manufacturing trains, or changes in analytical methods. ICH Q5E and the FDA's 2017 guidance "Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA" provide frameworks for managing these changes.

A comparability protocol is a comprehensive, prospectively written plan for assessing the effect of a proposed post-approval CMC change on the identity, strength, quality, purity, and potency of the product. The protocol defines:

• The specific change to be implemented
• The analytical testing to be performed (pre-change and post-change)
• The acceptance criteria for comparability (based on known product variability and clinical relevance)
• The reporting category for the change (Prior Approval Supplement, Changes Being Effected in 30 Days, or Annual Report)

For peptide biosimilars, comparability protocols are particularly useful for anticipated changes such as scale-up of solid-phase peptide synthesis, changes in preparative HPLC resins or column dimensions, and optimization of lyophilization cycles.

Interchangeability Standards

The Interchangeability Threshold

The BPCI Act provides that a biological product may be determined to be interchangeable with the reference product if it meets the biosimilarity standard (highly similar, no clinically meaningful differences) and additionally meets the interchangeability standard:

1. The product can be expected to produce the same clinical result as the reference product in any given patient
2. For a product administered more than once, the risk in terms of safety or diminished efficacy of alternating or switching between the product and the reference product is not greater than the risk of using the reference product without such alternation or switch

The interchangeability standard is higher than the biosimilarity standard: it requires not only that the products are equivalent at the population level but that they can be substituted at the pharmacy level without prescriber intervention (depending on state pharmacy laws) and that patients can be switched from reference product to biosimilar without loss of efficacy or increase in safety risk.

Demonstrating Interchangeability

The FDA's 2019 draft guidance (finalized 2024) on "Considerations in Demonstrating Interchangeability with a Reference Product" outlines the regulatory expectations for demonstrating interchangeability, which include:

Switching study design: A dedicated switching study is generally required, in which patients are randomized to either remain on the reference product throughout the study period or alternate between the reference product and the proposed interchangeable product (at least two alternations). The study compares the pharmacokinetics (and, where clinically meaningful, the efficacy and immunogenicity) between the switched and non-switched groups.

Statistical approach: The switching study is designed to demonstrate that switching does not result in reduced efficacy or increased safety risk compared to continuous reference product treatment. The primary endpoints typically include PK parameters (AUC, Cmax) assessed by the 90% CI within 80–125% equivalence limits, and — depending on the therapeutic area — clinical efficacy endpoints and immunogenicity rates.

Duration and endpoints: The duration of the switching study and the endpoints assessed depend on the clinical context — the indication, the pharmacokinetics of the product, the known immunogenicity profile, and the expected time course for the development of an immune response. For peptides with short half-lives (hours) and low immunogenic potential, a shorter PK-based switching study may be adequate; for peptides with longer half-lives (days) or with known immunogenic potential, a longer study including immunogenicity endpoints is required.

Global Interchangeability Standards

Interchangeability designation is a U.S.-specific regulatory construct; other jurisdictions address substitutability differently:

European Union: The EMA does not grant an "interchangeability" designation. Instead, decisions regarding substitution (automatic substitution at the pharmacy level) are made by individual EU member states. The EMA's role is limited to determining biosimilarity and providing the scientific basis for national substitution decisions through the European Public Assessment Report (EPAR).

Japan: The PMDA approves biosimilars but does not make separate interchangeability determinations. Substitution decisions are based on clinical practice guidelines and institutional policies.

WHO: The WHO guidelines on evaluation of similar biotherapeutic products provide a framework for biosimilar evaluation adopted by many non-ICH countries, emphasizing stepwise comparability but not addressing interchangeability as a separate regulatory determination.

Global Regulatory Harmonization

ICH Contributions to Biosimilar Harmonization

While ICH has not issued a dedicated biosimilar guideline, several ICH guidelines are directly applicable to biosimilar development and regulatory review:

• ICH Q5E (Comparability) establishes the framework for demonstrating that manufacturing changes do not affect product quality
• ICH Q6B (Specifications for Biotechnological Products) provides guidance on setting specifications for biologic products
• ICH Q8–Q12 (Quality by Design, Risk Management, Quality Systems) establish the modern risk-based quality framework applicable to both reference products and biosimilars
• ICH E9(R1) (Estimands) provides the framework for defining treatment effects in comparative clinical trials, directly applicable to biosimilar clinical study design

Beyond ICH, the International Pharmaceutical Regulators Programme (IPRP) Biosimilars Working Group facilitates information sharing and regulatory convergence among member authorities, and bilateral regulatory collaborations (e.g., FDA–EMA Parallel Scientific Advice) enable sponsors to seek harmonized feedback from multiple agencies during biosimilar development.

WHO Guidelines and Global Access

The WHO's 2009 "Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs)" — updated in 2022 — provide a globally applicable framework for biosimilar evaluation that has been adopted or adapted by regulatory authorities in many low- and middle-income countries. The guidelines establish:

• A reference product selection framework
• Quality evaluation criteria emphasizing comprehensive analytical comparison
• Nonclinical and clinical evaluation strategies proportionate to the residual uncertainty following analytical comparison
• Pharmacovigilance and post-marketing surveillance requirements

The WHO guidelines have been instrumental in expanding global access to biosimilar peptide products by providing a scientifically rigorous framework that does not require the extensive clinical trial infrastructure that may be unavailable in some regions.

Regional Convergence and Divergence

Despite substantial progress in global harmonization, important regional differences persist:

Aspect	FDA (United States)	EMA (European Union)	PMDA (Japan)	WHO (Global)
Regulatory pathway	351(k) BLA	Centralized MAA (Reg 726/2004)	Biosimilar application under PMD Act	Adapted by member states
Interchangeability designation	Yes — separate determination	No — member state substitution decisions	No formal designation	Not addressed
Switching study requirement	Generally required for interchangeability	Not required; switching data may be submitted	Not routinely required	Not required
Clinical study expectations	At least one comparative efficacy/safety study typically required	At least one comparative efficacy/safety study typically required	May use foreign data (bridging)	Proportional to residual uncertainty
Extrapolation of indications	Permitted with scientific justification	Permitted with scientific justification	Case-by-case assessment	Permitted with scientific justification

Research Evidence — Biosimilar Approval Landscape

The following table summarizes key approved biosimilar/follow-on peptide and protein products and their regulatory precedents:

Product	Active Substance	Reference Product	Approving Authority	Year	Key Precedent
Omnitrope	Somatropin (rhGH)	Genotropin	EMA	2006	First biosimilar approved in Europe; established analytical comparability paradigm
Omnitrope	Somatropin (rhGH)	Genotropin	FDA	2006*	Follow-on protein approved under 505(b)(2) prior to BPCI Act pathway
Zarxio	Filgrastim (G-CSF)	Neupogen	FDA	2015	First biosimilar approved under 351(k) pathway; established biosimilar naming convention
Basaglar	Insulin glargine	Lantus	FDA	2015	Follow-on insulin approved under 505(b)(2); later transitioned to biologic regulation
Semglee	Insulin glargine	Lantus	FDA	2021	First interchangeable biosimilar insulin product approved

*Approved as a follow-on protein under 505(b)(2) prior to BPCI Act implementation; subsequently deemed a biologic.

These precedents illustrate the evolution of the biosimilar regulatory framework and the variable classification of peptide products (drug vs. biologic) based on size, manufacturing method, and the date of the regulatory submission relative to the transition provisions of the Further Consolidated Appropriations Act of 2020.

Current Understanding

The regulatory framework for biosimilar peptides has matured substantially since the enactment of the BPCI Act in 2010. The scientific and regulatory consensus reflects several key principles:

The totality-of-the-evidence approach works: The stepwise, hierarchical approach — analytical similarity as the foundation, supplemented by targeted nonclinical and clinical data as needed to resolve residual uncertainty — has proven scientifically rigorous and operationally viable. For well-characterized peptides, analytical similarity can be demonstrated with high confidence, allowing reduction in the scope of clinical data required.

Analytical methods continue to advance: The increasing sensitivity and resolution of mass spectrometry, the growing sophistication of biophysical characterization techniques, and the development of more sensitive and mechanism-reflective potency assays are progressively enhancing the ability to detect meaningful differences between reference and biosimilar products. This analytical evolution may, over time, enable further reduction in the clinical data requirements for biosimilar approval, consistent with the FDA's expressed intent to move toward a more analytically driven biosimilar assessment paradigm.

Interchangeability remains an evolving standard: The interchangeability designation — unique to the U.S. regulatory framework — has generated the most debate and represents the area of greatest regulatory evolution. The FDA's 2024 final interchangeability guidance reflects a gradual shift toward greater flexibility, including the recognition that switching studies may not always require a three-switch design and that, for some products, PK-based switching studies may be acceptable. The global trend is toward greater acceptance of switching and substitution, supported by accumulating real-world evidence from health systems that have implemented biosimilar switching policies.

Global harmonization is advancing but incomplete: The convergence of biosimilar standards across ICH member countries — facilitated by WHO guidelines, IPRP collaboration, and bilateral regulatory interactions — has reduced barriers to global biosimilar development. However, important differences remain, particularly regarding interchangeability, clinical data expectations for extrapolation to non-studied indications, and naming conventions. Industry and regulatory collaboration through ICH and IPRP will continue to be essential.

The RPL Peptide Data Center provides analytical reference data that can support biosimilar characterization programs, and RPL Peptide offers research-grade peptide materials suitable for analytical method development in biosimilar programs.

Future Research Directions

• Analytical-driven biosimilarity: The continued development of high-resolution analytical techniques — including native mass spectrometry for higher-order structure, hydrogen-deuterium exchange mass spectrometry (HDX-MS) for conformational dynamics, and advanced NMR methods for solution structure — will progressively increase the confidence with which biosimilarity can be demonstrated analytically. The FDA has signaled interest in moving toward a paradigm in which robust analytical similarity, together with PK/PD data, may be sufficient for biosimilar approval in some cases, reducing or eliminating the requirement for comparative clinical efficacy studies.
• Quantitative structure-activity relationship (QSAR) approaches: The application of machine learning to predict the clinical impact of analytical differences between reference and biosimilar products — linking specific analytical differences to pharmacokinetic, pharmacodynamic, or immunogenic outcomes — could transform the biosimilar assessment from an empirical to a predictive exercise.
• Real-world evidence (RWE) for biosimilar switching: As healthcare systems accumulate experience with biosimilar switching, real-world data on safety, efficacy, and immunogenicity in routine clinical practice could complement or reduce the need for prospective switching studies for interchangeability determinations.
• Pharmacovigilance and traceability: The development of robust systems for tracing biosimilar products to specific manufacturers and lot numbers in electronic health records and adverse event reporting databases remains an operational challenge. Blockchain and other distributed ledger technologies have been proposed to enhance traceability and support post-marketing safety surveillance.
• Biosimilar peptides in emerging markets: The adaptation of WHO biosimilar guidelines to the regulatory capacities, healthcare infrastructures, and disease priorities of low- and middle-income countries represents an ongoing challenge. Research on pragmatic biosimilar evaluation frameworks that provide adequate assurance of safety and efficacy while acknowledging local constraints is needed.
• Naming and labeling harmonization: The international divergence in biosimilar naming conventions — the FDA's four-letter suffix system, the EMA's reliance on brand name and INN (International Nonproprietary Name), and the WHO's biological qualifier proposal — creates confusion and risks medication errors. Harmonized global naming standards for biosimilar products, including peptides, remain an important policy objective.

Frequently Asked Questions

What is the difference between a biosimilar peptide and a generic peptide drug?

A generic drug (approved under an ANDA) is a chemically identical copy of a small-molecule reference listed drug, demonstrated to be pharmaceutically equivalent and bioequivalent. A biosimilar (approved under a 351(k) BLA) is a biological product demonstrated to be highly similar to and have no clinically meaningful differences from an FDA-licensed reference biologic product. The fundamental difference is that small-molecule drugs can be fully characterized and reproduced as identical chemical entities, whereas biologic products — including certain peptides — are complex macromolecules whose properties depend on the manufacturing process, cell line, and purification steps. Consequently, a biosimilar is not an "identical" copy but a "highly similar" one, and the approval pathway requires a more extensive demonstration of similarity — including analytical, nonclinical, and clinical data — than the bioequivalence demonstration required for generic drugs. For chemically synthesized peptides of fewer than 40 amino acids regulated as drugs, the generic pathway (ANDA) may be available via a suitability petition; for larger or recombinantly produced peptides regulated as biologics, the biosimilar pathway (351(k)) applies.

How does the FDA determine whether a proposed biosimilar peptide is "highly similar" to the reference product?

The FDA determines that a proposed biosimilar is "highly similar" based on a comprehensive analytical comparison that demonstrates that the proposed product shares the same primary amino acid sequence, comparable higher-order structure, comparable post-translational modifications, and comparable purity/impurity profiles as the reference product — with any observed differences justified as not clinically meaningful. The assessment is organized in a tiered approach: Tier 1 attributes (most critical to clinical outcome, such as potency) are evaluated using formal statistical equivalence testing; Tier 2 attributes (supportive of similarity) are evaluated against quality ranges derived from reference product data; and Tier 3 attributes (descriptive) are compared graphically. The FDA evaluates the totality of the analytical data, and the demonstration of highly similar analytical profiles across all attributes forms the foundation upon which the need for further nonclinical and clinical data is assessed. A finding of "high similarity" does not require that every analytical attribute be identical between the products — minor differences are expected and acceptable provided they are understood and not clinically relevant.

Is a switching study always required for biosimilar peptide interchangeability?

Under the FDA's current guidance, a switching study is generally required for an interchangeability determination for products administered more than once, unless the sponsor provides a scientific justification for why a switching study is not needed. A switching study involves at least two alternations between the reference product and the proposed interchangeable product, comparing PK (and, depending on the product, clinical endpoints and immunogenicity) between the switched and non-switched treatment groups. However, the FDA has acknowledged that for certain products — particularly those with short half-lives, low immunogenic potential, and PK-based endpoints that are sensitive to product differences — a PK-based switching study without additional clinical endpoints may be adequate. For peptides with short half-lives (hours) and minimal immunogenic risk, the switching study may be limited to a PK crossover design with adequate washout. For peptides with longer half-lives or known immunogenic potential, a longer-duration study including immunogenicity assessment is likely to be required. The specific design should be discussed with the FDA through the biosimilar product development (BPD) meeting process.

Can a biosimilar peptide be approved for indications not directly studied in the biosimilar's clinical program?

Yes, a biosimilar peptide may be approved for one or more indications of the reference product for which the biosimilar was not directly studied in clinical trials, a process known as extrapolation. Extrapolation is scientifically justified when: (1) the mechanism of action of the product is the same across the requested indications (e.g., the peptide hormone binds the same receptor in all indications); (2) the biosimilarity demonstration — including comprehensive analytical characterization, PK/PD similarity, and at least one comparative clinical study — provides a convincing body of evidence that there are no clinically meaningful differences; (3) there is adequate scientific justification for extrapolating safety and immunogenicity data from the studied indication to the non-studied population; and (4) the non-studied indication does not present unique considerations (different patient population, different concomitant medications, different immunocompetence status) that would make extrapolation inappropriate. The FDA, EMA, and PMDA all permit indication extrapolation when scientifically justified, and this principle has been applied to biosimilar approvals of G-CSF products, insulins, and other peptide/protein therapeutics.

How does the 12-year reference product exclusivity period affect biosimilar peptide development?

Under the BPCI Act, a reference biologic product approved under Section 351(a) receives 12 years of exclusivity from the date of first licensure, during which a biosimilar application under Section 351(k) referencing that product cannot be approved. Additionally, no biosimilar application can be submitted until 4 years after the reference product's licensure date. This exclusivity period provides the reference product sponsor with significant protection: 4 years of data exclusivity (no biosimilar applications can be submitted), followed by 8 years of market exclusivity (during which the application can be submitted and reviewed but not approved until the 12-year mark), for a total of 12 years. This is substantially longer than the 5-year new chemical entity exclusivity for drugs approved under NDAs. For peptide sponsors considering whether to develop a product as a drug or biologic, the exclusivity implications are significant: a 351(a) BLA provides 12 years of exclusivity, while a 505(b)(1) NDA provides 5 years. The 12-year period applies from the date of reference product licensure, not patent expiration, and operates independently of any patent protection. Pediatric exclusivity (6 months) may extend the exclusivity period if pediatric studies are conducted.

What is a comparability protocol and how is it used in biosimilar peptide development?

A comparability protocol is a comprehensive, prospectively written plan for assessing the effect of a proposed post-approval CMC change on the identity, strength, quality, purity, and potency of a biological product. For biosimilar peptides, comparability protocols are used to manage manufacturing changes that may occur during the product lifecycle, such as: changes in cell line or fermentation conditions (for recombinant peptides), changes in SPPS scale or synthesizer type (for chemically synthesized peptides), changes in purification media or conditions, introduction of new analytical methods, or changes in formulation or container/closure system. The comparability protocol is submitted to the regulatory authority for review and approval and — if approved — allows the sponsor to implement the change under a reduced reporting category (e.g., Changes Being Effected in 30 Days rather than Prior Approval Supplement). The comparability paradigm also applies during biosimilar development, where comparability between pre-change and post-change development lots must be demonstrated to ensure that process optimization has not altered the product's biosimilarity to the reference product.

How does the EMA's biosimilar framework differ from the FDA's for peptide products?

The EMA and FDA biosimilar frameworks are broadly harmonized in their scientific principles — both employ a stepwise, totality-of-the-evidence approach emphasizing analytical comparability, and both require at least one comparative clinical study in most cases. Key differences include: (1) Interchangeability — the FDA has a distinct, higher-standard interchangeability designation requiring a switching study; the EMA makes no such designation, leaving substitution decisions to individual EU member states. (2) Reference product sourcing — the EMA requires that the reference product used in comparability studies be sourced from the European Economic Area (EEA); the FDA requires a U.S.-licensed reference product, though a bridging study with a non-U.S.-licensed comparator can be used. (3) Product-class-specific guidances — the EMA has published extensive product-class-specific biosimilar guidelines (including for insulins and G-CSF), while the FDA has issued fewer class-specific guidances with the expectation that the general principles articulated in overarching guidances apply. (4) Naming — the EMA uses the International Nonproprietary Name (INN) without a suffix; the FDA uses the INN plus a unique four-letter suffix.

What immunogenicity data is required for biosimilar peptide approval?

Immunogenicity assessment is a critical component of the biosimilarity demonstration because anti-drug antibodies (ADAs) to therapeutic peptides can affect pharmacokinetics (altered clearance), pharmacodynamics (neutralization of biological activity), and safety (hypersensitivity reactions, immune complex disease). For biosimilar peptides, immunogenicity assessment involves: (1) Analytical characterization demonstrating comparable aggregation levels, comparable levels of product-related variants that may enhance immunogenicity (oxidized species, deamidated species), and comparable levels of process-related impurities that may have adjuvant effects; (2) A multi-tiered bioanalytical approach in the comparative clinical study — screening assay (detecting any ADA), confirmatory assay (confirming specificity of detected ADA), titer determination, and neutralizing antibody assay (determining whether ADA inhibit the biological activity); (3) Comparative ADA incidence, titer, time course, and neutralizing capacity between the proposed biosimilar and reference product; and (4) Correlation of ADA responses with pharmacokinetics (altered exposure), pharmacodynamics (lost efficacy), and clinical safety (injection site reactions, hypersensitivity). Even if ADA incidence is low in both groups, the analytical similarity data and the clinical immunogenicity data together provide assurance that the biosimilar does not present a greater immunogenic risk than the reference product.

How are biosimilar peptide naming conventions determined?

The FDA's naming convention for biological products, including biosimilars, is described in the 2017 guidance "Nonproprietary Naming of Biological Products." Under this guidance, the FDA assigns each biological product a proper name that consists of the International Nonproprietary Name (INN) or core name plus a unique four-letter suffix. The suffix has no meaning (it is not an abbreviation), is lowercase, and is attached to the core name with a hyphen (e.g., filgrastim-sndz for the biosimilar Zarxio). The purpose of the suffix is to facilitate pharmacovigilance by enabling precise identification of the specific product associated with an adverse event report, prescription, or dispensing record. The EMA, in contrast, uses the INN without a suffix and relies on brand name plus batch number for traceability. Japan's PMDA uses the INN plus a suffix (typically the applicant name abbreviation). The WHO has proposed a Biological Qualifier (BQ) — a four-letter code assigned at the time of INN application — as a global harmonized identifier, but this proposal has not been fully adopted by major regulatory authorities.

What are the regulatory pathways for chemically synthesized peptide follow-on products vs. recombinant peptide biosimilars?

The regulatory pathway for a follow-on or biosimilar peptide product depends on the regulatory classification of the reference product. For reference products classified as drugs (typically chemically synthesized peptides of fewer than 40 amino acids), a follow-on product may be pursued through: (a) an ANDA (505(j)) with a suitability petition if the product meets the statutory definition of a drug suitable for the generic pathway, or (b) a 505(b)(2) NDA if additional data beyond bioequivalence are required (e.g., if the peptide formulation, manufacturing process, or impurity profile differs from the reference product). For reference products classified as biologics (recombinantly produced peptides regardless of size, and chemically synthesized polypeptides meeting the "protein" definition as of March 23, 2020), the biosimilar pathway under 351(k) applies. The FDA's March 2020 transition of certain chemically synthesized polypeptides from drug to biologic regulation under the BPCI Act means that products previously eligible for the 505(b)(2) pathway may now require a 351(k) biosimilar application. Sponsors should consult the FDA and the published lists of deemed biologic products to determine the correct pathway for their specific peptide.

References

1. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009. Public Law 111-148, Title VII, Subtitle A, Sections 7001–7003.
2. U.S. Food and Drug Administration. (2015). Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.
3. U.S. Food and Drug Administration. (2024). Guidance for Industry: Considerations in Demonstrating Interchangeability with a Reference Product. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.
4. European Medicines Agency. (2014). Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. EMA/CHMP/BMWP/42832/2005 Rev. 1.
5. World Health Organization. (2022). Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), Annex 2. WHO Technical Report Series, No. 1044.
6. International Council for Harmonisation. (2004). ICH Harmonised Tripartite Guideline: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process Q5E. ICH Secretariat, Geneva.
7. U.S. Food and Drug Administration. (2017). Guidance for Industry: Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA. Center for Drug Evaluation and Research.
8. European Medicines Agency. (2015). Guideline on Similar Biological Medicinal Products Containing Recombinant Human Insulin and Insulin Analogues. EMA/CHMP/BMWP/17375/2011 Rev. 1.
9. Kozlowski, S., Woodcock, J., Midthun, K., & Sherman, R. B. (2011). Developing the nation's biosimilars program. New England Journal of Medicine, 365(5), 385–388. DOI:10.1056/NEJMp1107285
10. Weise, M., Bielsky, M. C., De Smet, K., Ehmann, F., Ekman, N., Giezen, T. J., ... & Schneider, C. K. (2012). Biosimilars: what clinicians should know. Blood, 120(26), 5111–5117. DOI:10.1182/blood-2012-04-425744
11. Chow, S. C., Song, F., & Bai, H. (2016). Analytical similarity assessment in biosimilar studies. AAPS Journal, 18(3), 670–677. DOI:10.1208/s12248-016-9882-5
12. Christl, L. A., Woodcock, J., & Kozlowski, S. (2017). Biosimilars: the US regulatory framework. Annual Review of Medicine, 68, 243–254. DOI:10.1146/annurev-med-051215-031022
13. Kirchhoff, C. F., Wang, X. M., Conlon, H. D., Anderson, S., & Richardson, D. (2017). Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnology and Bioengineering, 114(12), 2696–2705. DOI:10.1002/bit.26427
14. Tsiftsoglou, A. S., Ruiz, S., & Schneider, C. K. (2013). Development and regulation of biosimilars: current status and future challenges. BioDrugs, 27(3), 203–211. DOI:10.1007/s40259-013-0020-y
15. U.S. Food and Drug Administration. (2017). Guidance for Industry: Nonproprietary Naming of Biological Products. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.